Company profile: Abpro
1.1 - Company Overview
Company description
- Provider of next-generation antibody therapeutics, diagnostics, and research solutions using DiversImmune and MultiMab platforms to discover and engineer high-affinity, high-specificity bi- and multi-specific antibodies against difficult targets, including the TetraBi tetravalent bispecific format for T-cell engagement with bivalent tumor antigen binding, Fc modification, and flexible configurations to enhance safety and efficacy.
Products and services
- Next-Generation Antibody Therapies: Abpro engineers platform-based therapeutics by integrating DiversImmune® and MultiMab™ to produce bi- and multi-specific antibodies for various diseases
- MultiMab™ Antibody Engineering Platform: Abpro constructs bi- and multi-specific therapeutic candidates by combining antibodies to enhance efficacy and safety
- DiversImmune® Antibody Discovery Platform: Abpro creates high-affinity/high-specificity antibodies against difficult therapeutic targets, supporting discovery of candidates used to build bi- and multi-specific therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Abpro
MetrioPharm
HQ: Switzerland
Website
- Description: Provider of clinical-stage pharmaceutical development for chronic inflammatory diseases including psoriasis, arthritis, and multiple sclerosis. Offers MP1032, an oral immune modulator that normalizes energy metabolism of inflammatory immune cells and reduces corticosteroid-associated side effects without immunosuppression, with Phase IIa efficacy in psoriasis and COVID-19 and preclinical efficacy in Rheumatoid Arthritis and Duchenne muscular dystrophy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MetrioPharm company profile →
Vir Biotechnology
HQ: United States
Website
- Description: Provider of immunology-based products to treat and prevent infectious diseases and other serious conditions, including Phase 2 tobevibart + elebsiran for chronic hepatitis delta and elebsiran + PEG-IFN-α for chronic hepatitis B; Phase 1 VIR-1388 for HIV prevention; and preclinical candidates VIR-8190 (RSV & hMPV), VIR-2981 (influenza A/B), and VIR-1949 (pre-cancerous HPV lesions).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vir Biotechnology company profile →
BioVaxys
HQ: Canada
Website
- Description: Provider of immunotherapeutic cancer vaccines and delivery platforms. Haptenix uses haptens to train the immune system to recognize tumor or viral proteins; DPX is a lipid-based system for enhanced, sustained immune responses. Pipeline includes BVX-0918 (Phase I ovarian), Maveropepimut-S (DPX-formulated, Phase II for various cancers), and DPX SurMAGE (survivin/MAGE A9; bladder, lung, kidney; Phase I complete).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVaxys company profile →
MolMed
HQ: Italy
Website
- Description: Provider of medical biotechnology research, development and clinical validation of novel anticancer therapies. The pipeline includes antitumour therapeutics in clinical and preclinical development, including Zalmoxis (TK), a cell-based therapy enabling bone marrow transplants from partially compatible donors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MolMed company profile →
Xyphos
HQ: United States
Website
- Description: Provider of CAR-T cell therapy platforms for treating relapsed hematological malignancies and solid tumors. Offers ACCEL, which uses engineered ligands to precisely control activity and targeting of universal convertibleCAR-T with tumor-specific antibodies, and ConvertibleCAR, a technology modifying NKG2D to enable flexible multi-antigen targeting and enhanced immune cell activation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xyphos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Abpro
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Abpro
2.2 - Growth funds investing in similar companies to Abpro
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Abpro
4.2 - Public trading comparable groups for Abpro
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →